

Our commitment to transparency

Commitment to transparency in financial relationships with healthcare professionals and healthcare organisations.

Novo Nordisk is committed to doing everything we can to improve the treatment of diabetes and other chronic conditions. This includes providing as much information as we can to healthcare professionals, healthcare organisations and patients about the proper use of the medicines and delivery systems we manufacture.

Collaborations with healthcare professionals and healthcare organisations help us drive innovation and develop new medicines, enhance quality of health education and identify patient needs.

Novo Nordisk supports transparency and is committed to compliance with disclosing our financial relationships related to our collaborations with the medical community as required by our industry guidelines, namely the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice.

We believe the transparency of financial relationships between those with whom we collaborate is very important to maintaining trust-based relationships with our patients and the public.

Please refer to the Declaration of Sponsorship link for the transactions Novo Nordisk has made to patient organisations in 2017. As a member of the IPHA, Novo Nordisk is required to make public details of payments and transfer of value (ToV) or in kind made to Irish healthcare professionals and healthcare organisations in 2017. This ToV will be published in June 2018 on www.transferofvalue.ie.

IR/WB/1214/0044b(2)

Date of preparation: April 2018

The Apis bull logo is a registered trademark of Novo Nordisk A/S

